Maher M. Haddad

Array ( [id] => 16012743 [patent_doc_number] => 20200181214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => FUSION PROTEINS FOR INHIBITING ANGIOGENESIS [patent_app_type] => utility [patent_app_number] => 16/803561 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13812 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16803561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283783 [patent_doc_number] => 20200277385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => Anti-CD303 Monoclonal Antibodies [patent_app_type] => utility [patent_app_number] => 16/799703 [patent_app_country] => US [patent_app_date] => 2020-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25482 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16799703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236843 [patent_doc_number] => 20200254077 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => Materials and Methods for Eliciting Targeted Antibody Responses In Vivo [patent_app_type] => utility [patent_app_number] => 16/797661 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17780 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16797661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16512974 [patent_doc_number] => 20200392232 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => INTEGRIN BETA7 ANTAGONISTS AND METHODS OF TREATING CROHN'S DISEASE [patent_app_type] => utility [patent_app_number] => 16/795296 [patent_app_country] => US [patent_app_date] => 2020-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37925 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16795296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012783 [patent_doc_number] => 20200181234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/792925 [patent_app_country] => US [patent_app_date] => 2020-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22412 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16792925 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17958668 [patent_doc_number] => 20220339248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => METHODS FOR TREATING NEOINTIMAL HYPERLASIA USING F11R/JAM-A INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/596699 [patent_app_country] => US [patent_app_date] => 2020-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17596699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17975558 [patent_doc_number] => 11492406 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-08 [patent_title] => Methods and compositions for treating and preventing disease associated with alpha-v beta-8 integrin [patent_app_type] => utility [patent_app_number] => 16/791975 [patent_app_country] => US [patent_app_date] => 2020-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 11491 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 722 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16791975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16222784 [patent_doc_number] => 20200247900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A [patent_app_type] => utility [patent_app_number] => 16/788251 [patent_app_country] => US [patent_app_date] => 2020-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26032 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16788251 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17557169 [patent_doc_number] => 11313864 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Method for determining anti-drug antibodies in a minipig sample [patent_app_type] => utility [patent_app_number] => 16/783623 [patent_app_country] => US [patent_app_date] => 2020-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 13556 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 221 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16783623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17007127 [patent_doc_number] => 20210238288 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/781647 [patent_app_country] => US [patent_app_date] => 2020-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36899 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16781647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093153 [patent_doc_number] => 20220411494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => CONNEXIN 43 ANTIBODIES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/767171 [patent_app_country] => US [patent_app_date] => 2020-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18753 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18134780 [patent_doc_number] => 11560433 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-24 [patent_title] => Methods of treatment by targeting VCAM1 and MAEA [patent_app_type] => utility [patent_app_number] => 16/773907 [patent_app_country] => US [patent_app_date] => 2020-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 114 [patent_figures_cnt] => 221 [patent_no_of_words] => 25921 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16773907 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16512958 [patent_doc_number] => 20200392216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT [patent_app_type] => utility [patent_app_number] => 16/750978 [patent_app_country] => US [patent_app_date] => 2020-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16750978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16156655 [patent_doc_number] => 20200216560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => Anti-MCAM Antibodies And Associated Methods Of Use [patent_app_type] => utility [patent_app_number] => 16/745178 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36227 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16745178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16656097 [patent_doc_number] => 20210052733 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/743813 [patent_app_country] => US [patent_app_date] => 2020-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30308 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16743813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16175495 [patent_doc_number] => 20200222463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => Pharmaceutical Composition for Cancer Treatment [patent_app_type] => utility [patent_app_number] => 16/732764 [patent_app_country] => US [patent_app_date] => 2020-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16732764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403677 [patent_doc_number] => 20240287188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => ANTIBODY SPECIFICALLY BINDING TO ICAM-1 AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/312083 [patent_app_country] => US [patent_app_date] => 2019-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15915419 [patent_doc_number] => 10654939 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-05-19 [patent_title] => Antibodies specific to CD40 and uses thereof [patent_app_type] => utility [patent_app_number] => 16/724409 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 56 [patent_no_of_words] => 19162 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16724409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15915417 [patent_doc_number] => 10654938 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-05-19 [patent_title] => CD40 binding antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/724396 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 56 [patent_no_of_words] => 19119 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16724396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15882887 [patent_doc_number] => 10647776 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-05-12 [patent_title] => Anti-CD40 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/724407 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 56 [patent_no_of_words] => 19176 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16724407 [rel_patent_id] =>[rel_patent_doc_number] =>)